This study is designed as a Phase 2b, randomized trial to evaluate the efficacy and safety of TGR-1202 alone and in combination with ublituximab with or without bendamustine in previously treated indolent non-Hodgkins lympoma (iNHL) and Diffuse Large B-Cell Lymphoma (DLBCL) patients. Following screening, qualified patients with Follicular Lymphoma ( FL) or Small Lymphocytic Lymphoma (SLL) will be randomized in a 1:1 ratio to one of two arms: Arm A: Ublituximab + TGR-1202, Arm B: TGR-1202.

This is a randomized, placebo-controlled, double-blind, parallel group, multicenter, CV outcomes study in subjects with HFrEF, including subjects with ongoing or history of HF hospitalization. The study is event-driven and will conclude when approximately 1590 CV death events have occurred. Approximately 8000 eligible subjects will be randomized in a 1:1 ratio to receive either OM or placebo.

This study is a prospective multicenter double-blind randomized controlled trial. It will recruit patients with SCAF (Sub-Clinical Atrial Fibrillation) detected by either a pacemaker, an ICD (implantable cardioverter defibrillator) or an insertable cardiac monitor (ICM); who also have other risk factors for stroke (previous stroke/TIA or systemic arterial embolism OR age ? 75 OR age 65-74 with ? 2 other risk factors OR age 55-64 with ? 3 other risk factors). Eligible and consenting patients will be randomized to receive aspirin or apixaban.

Inecalcitol is a vitamin D receptor (VDR) agonist, a chemically modified analogue of calcitriol the active form of natural Vitamin D3. Inecalcitol is a novel synthetic vitamin D analogue developed by Hybrigenics. Inecalcitol was found to be 10 times more potent and 100 times less toxic than calcitriol. In addition to their well-known effects on calcium and phosphate homeostasis, calcitriol and VDR agonists are being increasingly recognized for their potent role in cell proliferation, differentiation, and immunomodulation.

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis. The objectives of this trial are to demonstrate the efficacy of RPC1063 versus placebo on induction of clinical remission and maintenance therapy on clinical remission. The trial is composed of 2 periods: Induction and Maintenance. Patients will be entered into the trial in 2 separate cohorts through the Induction Period and those patients in clinical response at the end of the Induction Period will proceed through to the Maintenance Period.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of Cenicriviroc (CVC) for the treatment of Stage 2 to 3 liver fibrosis in adult subjects with Non-Alcoholic Steatohepatitis (NASH). The study will be conducted in 2 parts: Part 1 (surrogate endpoint) and Part 2 (clinical outcomes). Part 1: Approximately 1000 subjects will be randomized. Approximately 667 subjects are to receive CVC and approximately 333 subjects are to receive placebo. Subjects who remain in Part 1 at Month 12 will continue to receive the same treatment assignment in Part 2.

This is a multiple-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled, parallel-group study and/or an open-label single-blind cohort when administered for 12 weeks as a daily SC injection in patients with histologically confirmed NASH. Patients to be studied will have histologically confirmed NASH as defined by the NIH NASH Clinical Research Network and determined by a qualified site pathologist.

This is a long-term extension study to evaluate the safety of filgotinib administered to subjects with Crohns Disease (CD).

This is a multicenter, double-blind, randomized, placebo-controlled, dose-response study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

This is a multicenter, double-blind, randomized, placebo-controlled, dose-response study to evaluate the safety and efficacy of emricasan in improving portal hypertension in subjects with NASH cirrhosis and severe portal hypertension (defined as hepatic venous pressure gradient (HVPG) ?12 mmHg). Subjects can have compensated (at least 60% of subjects but no more than 75%) or decompensated cirrhosis with no more than 1 prior significant decompensating event and must be currently clinically stable on stable standard therapy [2] (see Inclusion/Exclusion criteria).